The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this review, we summarise the safety, efficacy, potential transplantation routes and therapeutic effects of MSCs in patients with liver fibrosis. We also discuss some of the key strategies to enhance the functionality of MSCs, which include sorting and/or priming with factors such as cytokines, as well as genetic engineering.

中文翻译：

---

间充质基质细胞治疗肝病

间充质基质细胞 (MSC) 在治疗肝纤维化方面的治疗潜力主要基于其免疫抑制特性和分泌各种营养因子的能力。这种潜力已在临床和临床前研究中得到研究。尽管 MSC 移植的治疗机制仍未完全阐明，但越来越多的证据表明，MSC 分泌的各种营养因子通过减轻炎症、细胞凋亡和纤维化以及刺激受损肝脏的血管生成和组织再生，在再生中发挥关键治疗作用。在这篇综述中，我们总结了 MSCs 在肝纤维化患者中的安全性、有效性、潜在的移植途径和治疗效果。